Rate Hikes Return: The World Forgot Rates Only Go One Way
Start with New Zealand, because it matters more than its size suggests.
A pharmaceutical trial fails, a Pacific central bank raises rates for the first time in three years, Japanese workers see their wages climb, and somewhere inside the Federal Reserve's meeting minutes, several policymakers quietly suggest that borrowing costs are not actually restrictive enough. Pull these threads together and you get the same picture from four different angles: the era of cheap money is not returning on anyone's schedule.
Start with New Zealand, because it matters more than its size suggests. The Reserve Bank of New Zealand just raised rates — the first hike in three years — and Governor Adrian Orr called it a growth "rebound." That framing deserves scrutiny. Central banks don't raise rates into a rebound because they're generous. They raise rates because inflation is persisting into the recovery, which is the harder problem. A recovery with sticky prices is not a clean recovery. It is a negotiation between growth and control, and control just spoke first.
Japan tells a parallel story. Wages are rising there in a way that hasn't happened in a generation, and the Bank of Japan is watching it with something close to relief. For three decades, Japan tried to generate inflation and couldn't. Now it has both wages and prices moving, and the BoJ is normalising — carefully, deliberately, but normalising. The significance extends far beyond Tokyo: Japan's bond market is the largest in the world, and when Japanese rates rise, capital that has been parked there for yield returns home. That is a structural shift, not a headline.
Meanwhile the Fed's own minutes show a central bank more divided and more hawkish than its public posture suggests. "Several" members questioned whether current rates are even restrictive. The word several in Fed-speak is not casual. It signals a contingent prepared to move — and the new IMF inflation projections, revised upward alongside the collapse of the Iran ceasefire, give that contingent more ammunition than they had a month ago.
China sits at the other end of this map. Consumer prices weakened in June while producer prices rose to a near four-year high — the classic squeeze of an economy with robust exports and a domestic consumer who isn't spending. Investors have largely accepted this as structural. The question is whether deflation exported from China can offset inflation generated by energy markets and wage growth elsewhere. My read: it cannot, not indefinitely, not with oil where it is.
Then AstraZeneca dropped 9% after a late-stage heart drug trial missed its primary endpoint. A single trial failure does not define a company, but a 9% single-session move in a large-cap pharmaceutical is a reminder that equity markets are not pricing in much margin for error right now. When sentiment is bullish and positions are crowded — dollar longs are at a decade high — the correction when it comes is not gentle.
For anyone in Malta with a variable mortgage, a pension in equities, or a business exposed to dollar-denominated costs: the direction of travel is more expensive money, for longer. Plan accordingly.
